Price T Rowe Associates Inc Autolus Therapeutics PLC Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,841,502 shares of AUTL stock, worth $8.68 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,841,502
Previous 4,414,087
12.97%
Holding current value
$8.68 Million
Previous $15.4 Million
9.22%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AUTL
# of Institutions
104Shares Held
163MCall Options Held
2.8KPut Options Held
13.4K-
Wellington Management Group LLP Boston, MA24.2MShares$54.7 Million0.02% of portfolio
-
Blackstone Inc New York, NY20.5MShares$46.3 Million0.35% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X018.6MShares$41.9 Million83.42% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$34.5 Million2.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$27.9 Million0.67% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $205M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...